Advertisement
Research Article

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  • William Pao equal contributor mail,

    equal contributor Contributed equally to this work with: William Pao, Vincent A Miller

    To whom correspondence should be addressed. E-mail: paow@mskcc.org

    Affiliations: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Vincent A Miller equal contributor,

    equal contributor Contributed equally to this work with: William Pao, Vincent A Miller

    Affiliation: Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Katerina A Politi,

    Affiliation: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Gregory J Riely,

    Affiliation: Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Romel Somwar,

    Affiliation: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Maureen F Zakowski,

    Affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Mark G Kris,

    Affiliation: Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Harold Varmus

    Affiliation: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Published: February 22, 2005
  • DOI: 10.1371/journal.pmed.0020073

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.